The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).
Diletta Bianchini
No relevant relationships to disclose
Shahneen Kaur Sandhu
No relevant relationships to disclose
Amy Mulick Cassidy
No relevant relationships to disclose
Andrea Zivi
No relevant relationships to disclose
Janusz Mezynski
No relevant relationships to disclose
Deborah Mukherji
No relevant relationships to disclose
Carmel Jo Pezaro
No relevant relationships to disclose
Alison Helen Reid
No relevant relationships to disclose
Nikhil Babu Oommen
No relevant relationships to disclose
David Olmos
No relevant relationships to disclose
Aurelius Gabriel Omlin
No relevant relationships to disclose
Ajit Sarvadikar
No relevant relationships to disclose
Emilda Thompson
No relevant relationships to disclose
Joanne Hunt
No relevant relationships to disclose
Elizabeth Sheridan
No relevant relationships to disclose
Gerhardt Attard
Consultant or Advisory Role - Janssen-Cilag; Millennium; Veridex
Honoraria - Ipsen; Janssen-Cilag; Sanofi
Research Funding - AstraZeneca
Johann Sebastian De Bono
Employment or Leadership Position - ICR
Consultant or Advisory Role - Janssen Pharmaceutical
Honoraria - Janssen Pharmaceutical